Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) open the trading on Thursday, with a bit cautious approach as it glided -4.43% to $7.77, before settling in for the price of $8.13 at the close. Taking a more long-term approach, ARCT posted a 52-week range of $7.93-$24.17.
The Healthcare sector firm’s twelve-monthly sales growth has been -6.84% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -6.84%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 28.22%. This publicly-traded company’s shares outstanding now amounts to $27.23 million, simultaneously with a float of $24.87 million. The organization now has a market capitalization sitting at $210.99 million. At the time of writing, stock’s 50-day Moving Average stood at $16.40, while the 200-day Moving Average is $14.38.
Arcturus Therapeutics Holdings Inc (ARCT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arcturus Therapeutics Holdings Inc’s current insider ownership accounts for 8.42%, in contrast to 90.41% institutional ownership.
Arcturus Therapeutics Holdings Inc (ARCT) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year. Arcturus Therapeutics Holdings Inc’s EPS increase for this current 12-month fiscal period is 28.22% and is forecasted to reach -2.74 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 21.27% through the next 5 years, which can be compared against the -6.84% growth it accomplished over the previous five years trading on the market.
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcturus Therapeutics Holdings Inc (ARCT). It’s Quick Ratio in the last reported quarter now stands at 7.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.48.
In the same vein, ARCT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.46, a figure that is expected to reach -0.79 in the next quarter, and analysts are predicting that it will be -2.74 at the market close of one year from today.
Technical Analysis of Arcturus Therapeutics Holdings Inc (ARCT)
[Arcturus Therapeutics Holdings Inc, ARCT] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 14.45% While, its Average True Range was 23.06.
Raw Stochastic average of Arcturus Therapeutics Holdings Inc (ARCT) in the period of the previous 100 days is set at 0.06%, which indicates a major fall in contrast to 0.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.62 that was lower than 1.22 volatility it exhibited in the past 100-days period.
